Scanty fulfillment of the treatment in patients with glaucoma
08/06/2004 00:23
The patients, who receive prostaglandins to control their intraocular pressure, present very low fulfillment levels of the treatment, as indicates the information of a study that was presented by the European Glaucoma Society.
Dra. Gail F. Schwartz, of the Parris-Castoro Eye and Laser Center, at Maryland ( United States), presented the results of an analysis of the pharmacological records over 2.503 patients with glaucoma. Of them, until the end of the follow-up, 477 (19 %) interrupted the initial treatment and resumed it for 180 days. Other 40 patients (2 %) interrupted the treatment while they were using the medicament and resumed it later with prostaglandin.
Of 1.986 remaining patients, 879 (35 %) supported medication until the end; 280 (11 %) interrupted the treatment of prostaglandin and changed it into another type of medicament, but 827 (33 %) did not resume again.
|